Generic Qsymia Availability

Qsymia is a brand name of phentermine/topiramate, approved by the FDA in the following formulation(s):

QSYMIA (phentermine hydrochloride; topiramate - capsule, extended release;oral)

  • Manufacturer: VIVUS
    Approval date: July 17, 2012
    Strength(s): EQ 3.75MG BASE;23MG, EQ 7.5MG BASE;46MG, EQ 11.25MG BASE;69MG, EQ 15MG BASE;92MG [RLD]

Has a generic version of Qsymia been approved?

No. There is currently no therapeutically equivalent version of Qsymia available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Qsymia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Combination therapy for effecting weight loss and treating obesity
    Patent 7,056,890
    Issued: June 6, 2006
    Inventor(s): Najarian; Thomas
    Assignee(s): VIVUS, Inc.
    The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
    Patent expiration dates:
    • June 14, 2020
      ✓ 
      Patent use: USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
      ✓ 
      Drug product
  • Combination therapy for effecting weight loss and treating obesity
    Patent 7,553,818
    Issued: June 30, 2009
    Inventor(s): Najarian; Thomas
    Assignee(s): Vivus, Inc.
    The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
    Patent expiration dates:
    • June 14, 2020
      ✓ 
      Patent use: USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
  • Combination therapy for effecting weight loss and treating obesity
    Patent 7,659,256
    Issued: February 9, 2010
    Inventor(s): Najarian; Thomas
    Assignee(s): Vivus, Inc.
    The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
    Patent expiration dates:
    • June 14, 2020
      ✓ 
      Patent use: USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
      ✓ 
      Drug product
  • Combination therapy for effecting weight loss and treating obesity
    Patent 7,674,776
    Issued: March 9, 2010
    Inventor(s): Najarian; Thomas
    Assignee(s): Vivus, Inc.
    The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
    Patent expiration dates:
    • June 14, 2020
      ✓ 
      Patent use: USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
      ✓ 
      Drug product
  • Low dose topiramate/phentermine composition and methods of use thereof
    Patent 8,580,298
    Issued: November 12, 2013
    Assignee(s): Vivus, Inc.
    A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
    Patent expiration dates:
    • May 15, 2029
      ✓ 
      Drug product
  • Escalating dosing regimen for effecting weight loss and treating obesity
    Patent 8,580,299
    Issued: November 12, 2013
    Assignee(s): Vivus, Inc.
    The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.
    Patent expiration dates:
    • June 14, 2029
      ✓ 
      Patent use: USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 17, 2015 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web2)